Drug Profile
Research programme: gastrointestinal disease therapeutics - GlaxoSmithKline/Alimentary Pharmabiotic Centre
Latest Information Update: 19 Apr 2011
Price :
$50
*
At a glance
- Originator Alimentary Pharmabiotic Centre; GlaxoSmithKline
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory bowel diseases; Irritable bowel syndrome
Most Recent Events
- 28 Feb 2011 No development reported - Preclinical for Inflammatory bowel disease in Ireland (unspecified route)
- 28 Feb 2011 No development reported - Preclinical for Irritable bowel syndrome in Ireland (unspecified route)
- 22 Aug 2006 Preclinical trials in Inflammatory bowel disease in Ireland (unspecified route)